Skip to main content

Select Drug Profiles

In the Literature, Oncology
Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer
Read More
In the Literature, Oncology
Tisagenlecleucel Leads to High Rates of Durable Response in Relapsed, Refractory DLBCL
Read More
Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk Myelodysplastic Syndromes
Chase Doyle
Chase Doyle
Read More
Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes
Wayne Kuznar
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
Chase Doyle
Chase Doyle
Read More
Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia
Chase Doyle
Chase Doyle
Read More
Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018
Wayne Kuznar
Wayne Kuznar
Read More
Leukemia, Oncology
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma
Wayne Kuznar
Wayne Kuznar
Read More
Page 58 of 244
Results 571 - 580 of 2438